论文部分内容阅读
爱可泰隆新型肺动脉高压药物Uptravi(selexipag)的新药申请获美国FDA采用标准审评程序来审评。Uptravi新药申请在去年12月22日提交到美国FDA,爱可泰隆预测整个审评过程从现在算起要花费12个月。(源自:药品资讯网)
The new drug application for ictel’s new pulmonary hypertension drug Uptravi (selexipag) was reviewed by the U.S. FDA using a standard review procedure. Uptravi’s new drug application was submitted to the U.S. FDA on December 22 last year and it predicts the entire review process will take 12 months from now. (From: Drug Information Network)